These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Collagen-Coated Bovine Bone in Peri-implantitis Defects: A Pilot Study on a Novel Approach.
    Author: Rotenberg SA, Steiner R, Tatakis DN.
    Journal: Int J Oral Maxillofac Implants; 2016; 31(3):701-7. PubMed ID: 27183078.
    Abstract:
    PURPOSE: As dental implants have become routine therapy, clinicians are more frequently being faced with treating peri-implantitis. To date, no single treatment protocol has been shown to be the preferred means to treat peri-implantitis. The aim of this retrospective case series is to present a novel approach utilizing porcine collagen-coated bovine bone (CBB) to treat peri-implantitis. MATERIALS AND METHODS: Eleven patients, with no history of periodontitis, presenting with peri-implantitis around a single restored dental implant, were included in the study. At initial and follow-up examinations, bleeding on probing (BOP), probing depth (PD), and gingival margin location (GM) were recorded. Following surgical debridement of the peri-implant defect and treatment of the implant surface with a 0.12% chlorhexidine gluconate solution, bony defects were grafted with CBB. All patients had 12 months of follow-up. RESULTS: Upon presentation, average PD at the deepest site (DS) was 7.6 ± 1.9 mm. At the time of surgery, excess cement was found around nine implants (81%). All patients healed uneventfully without postoperative complications. At 6 and 12 months, all implants showed favorable results with average DS PD reduction of 3.9 ± 1.5 mm and 4.1 ± 1.6 mm, respectively. All implants showed radiographic signs of bone fill, while GM showed no changes from preoperative measurements at either 6 (0.1 ± 0.5 mm) or 12 (0.0 ± 0.6 mm) months. CONCLUSION: The use of a porcine collagen-coated bovine bone graft to treat peri-implantitis represents a potentially predictable therapeutic modality. Randomized controlled trials are necessary to substantiate the treatment outcomes.
    [Abstract] [Full Text] [Related] [New Search]